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Unusual absence of endothelium-dependent or -independent
vasodilatation to purines or pyrimidines in the rat renal artery
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Autonomic Neuroscience Institute, Royal Free and University College Medical School, London
Unusual absence of endothelium-dependent or -independent
vasodilatation to purines or pyrimidines in the rat renal artery.
Background. Adenosine triphosphate (ATP) is a cotrans-
mitter with noradrenaline (NA) in sympathetic perivascular
nerves. It has a dual role in the maintenance of vascular tone
as ATP, released from endothelial cells during shear stress or
hypoxia, induces vasodilatation via endothelial P2Y receptors
or by direct action on smooth muscle. The role and distribution
of P2 receptors is well characterized for many blood vessels
but not for the rat renal artery. This study aims to determine
whether ATP is a vasoconstrictor cotransmitter with NA and
whether ATP induces vasodilatation via the endothelium or
smooth muscle.
Methods. On isolated rat renal arteries, electrical field stimu-
lation (EFS) in the absence and presence of antagonists to P2X
receptors and 1-adrenoceptors was examined. Concentration-
response curves were constructed to NA, ATP, ,-methylene
ATP (,-meATP), uridine triphosphate (UTP), and 2-meth-
ylthio ADP (2-MeSADP) on low tone. Curves to acetylcholine
(ACh), 2-MeSADP, and UTP were constructed on raised tone.
Immunofluorescent localization of P2X and P2Y receptor sub-
types was performed.
Results. Electrical field stimulation induced vasoconstric-
tion, partially inhibited by the P2X receptor antagonist, pyri-
doxalphosphate-6-azophenyl-2‘,4-disulfonic acid, and predomi-
nantly by prazosin. Exogenous NA and ATP mimicked EFS;
immunostaining for P2X1 and P2X2 receptors was expressed
on vascular smooth muscle. Unusually, ATP, 2-MeSADP, and
UTP failed to induce vasodilatation. Acetylcholine induced
vasodilatation. ,-meATP, 2-MeSADP, and UTP induced va-
soconstriction via P2X1, P2Y1, and P2Y2 receptors, respectively.
Immunostaining for P2X1, P2Y1, and P2Y2 receptors was ex-
pressed on the vascular smooth muscle.
Conclusion. Adenosine triphosphate and NA are cotrans-
mitters in sympathetic nerves supplying the rat renal artery,
NA being the dominant partner. The novel feature of this
vessel is that purines and pyrimidines do not produce either
endothelium-dependent or -independent vasodilatation; P2X1,
P2Y1, and P2Y2 receptors on the smooth muscle all mediate
vasoconstriction.
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In 1929, Drury and Szent-Gyo¨rgyi [1] published data
describing the physiologic activities of extracellular ade-
nine compounds. Many studies followed, confirming the
role of purine nucleotides on the cardiovascular system
[2]. In 1972, Burnstock [3] proposed adenosine triphos-
phate (ATP) as a transmitter involved in non-adrenergic,
non-cholinergic (NANC), nerve-mediated responses of
smooth muscle in the gastrointestinal tract and bladder,
the term “purinergic” was coined, and the ATP receptors
termed purinoceptors. In 1978, Burnstock [4] proposed
that receptors selective for adenosine and adenosine mo-
nophosphate (AMP) be designated P1-purinoceptors
and those selective for ATP and adenosine diphosphate
(ADP) designated as P2-purinoceptors. Further subdivi-
sions followed: P1 receptors into A1, A2A, A2B, and A3
and P2 receptors into P2X and P2Y subtypes based on
pharmacologic profiles [5]. Later, on the basis of cloning
and signal transduction studies, P2 receptors were di-
vided into two families: a P2X ligand–gated ion channel
family and a P2Y G protein–coupled family [6]. Cur-
rently, seven subtypes of both P2X and P2Y families are
recognized [7–9].
There is dual purinergic control of vascular tone. Adeno-
sine triphosphate released from perivascular nerves acts
on P2X receptors on smooth muscle to mediate vasocon-
striction. Adenosine triphosphate released from endo-
thelial cells during changes in flow and hypoxia acts on
P2Y receptors producing vasodilatation [see 10, 11]. The
relative amounts of ATP and NA vary significantly in
sympathetic nerves in different blood vessels, for instance,
sympathetic transmission in guinea pig submucous arteri-
oles and rabbit mesenteric artery jejunal branches are
totally purinergic [12, 13], sympathetic transmission of
the rabbit splenic artery is largely purinergic [14], but in
the rabbit pulmonary artery it is almost entirely nor-
adrenergic [15]. In other blood vessels, such as the rabbit
saphenous vein, both ATP and NA contribute signifi-
cantly to sympathetic stimulation [16]. Exogenously ap-
plied ATP induces vasodilatation by an action at P2Y1
or P2Y2 receptors, located either on vascular endothelial
cells, leading to the release of nitric oxide (NO) and con-
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sequently, vasodilatation [7], or on P2Y receptors pres-
ent on vascular smooth muscle, for example, as with the
rabbit hepatic artery and portal vein [17, 18]. Uridine
triphosphate released from endothelial cells by shear
stress [19] stimulates endothelial P2Y2 receptors mediat-
ing vasodilatation via the production of NO [20]. P2Y2
receptors mediating vasoconstriction have been identi-
fied in some vessels, for example, in the rat mesenteric
arterial bed [21] and in the golden hamster mesenteric
arterial bed [22].
While considerable attention has been paid to the ef-
fects of purines on the renal vascular bed [23], there are
few studies of the isolated renal artery. In isolated pig
renal arteries, NA causes vasoconstriction of the artery
and prazosin partially inhibits electrically stimulated va-
soconstrictions [24]. Similarly, human extra- and intra-
renal arteries constrict in response to NA [25]. In other
studies on the rabbit and human renal arteries, ATP was
found to induce vasodilatation sensitive to inhibition by
the P1 receptor antagonist 8-p-(sulphophenyl) theophyl-
line, suggesting that in both humans and rabbits, the vaso-
dilatation is in part due to adenosine acting on smooth
muscle P1 purinoceptors after enzymatic breakdown of
ATP [26]. In the rabbit renal artery, adenosine and the
P2Y receptor agonists ADPS and 2-methylthio ATP
(2-MeSATP) induced vasodilatation, attenuated by the
antagonist, reactive blue 2. The presence of a nitric oxide
synthase (NOS) inhibitor had a strong inhibitory effect
on responses to 2-MeSATP, indicating that this agonist
was inducing endothelium-dependent vasodilatation via
the production of NO [26].
In this study of rat renal arteries, the aim was to investi-
gate whether ATP acts as a vasoconstrictor cotransmitter
with NA and whether ATP can induce vasodilatation
either via the endothelium or by direct action on smooth
muscle. To answer these questions, organ bath pharma-
cologic and immunohistochemical techniques were em-
ployed.
METHODS
Animals
Male Sprague-Dawley rats (250 to 300 g) were killed
by exposure to an increasing CO2 concentration and
death was ensured by cervical dislocation. This was in
accordance with the Home Office (UK) regulations (The
Humane Killing of Animals under Schedule One of the
Animals Scientific Procedures Act 1986) and principles
of good laboratory care were followed. After the abdom-
inal cavity was opened, the kidneys and renal arteries
were removed and placed in physiologic saline. The renal
arteries were then isolated from the kidneys and aorta
and cleared of surrounding fatty tissues under a dis-
secting microscope.
The isolated renal arteries were cut into rings of ap-
proximately 4 mm in length (this was almost the full
length of each artery) and suspended horizontally in
10 mL organ baths by inserting a tungsten wire through
the lumen of the vessel. Care was taken not to damage
the endothelium. A second tungsten wire was then in-
serted into the lumen; one end was attached to a rigid
support, the other to a Grass (Quincy, MA, USA) FT03C
force-displacement transducer. The organ baths con-
tained continuously gassed (95% O2/5% CO2) Kreb’s
solution of the following composition (mmol/L): NaCl
133, KCl 4.7, NaHPO4 1.35, NaHCO3 16.3, MgSO4 0.61,
glucose 7.8, CaCl2 2.52, pH 7.2, and maintained at 37 
1C. The ring preparations were placed under an initial
tension of 1 g and allowed to equilibrate for 1 hour prior
to the start of the experiments. Mechanical activity was
recorded using the software PowerLab Chart for Win-
dows (Version 4; ADInstruments, New South Wales,
Australia).
Transmural electrical field stimulation (EFS) was de-
livered to the vessel via platinum electrodes situated on
either side of the renal artery. The vessels were stimu-
lated (75 V, 0.1 millisecond, 1 to 32 Hz) for 10 seconds
at 5 minute intervals and a frequency-response curve
was constructed in the absence of any blocking agents.
On some preparations, a second frequency-response curve
was constructed in the presence of pyridoxalphosphate-
6-azophenyl-2,4-disulfonic acid (PPADS; 30 mol/L),
a non-selective P2 receptor antagonist, and then a third
frequency-response curve was constructed in the pres-
ence of both PPADS (30mol/L) and prazosin (3mol/L),
an 1-adrenoceptor antagonist. On other preparations,
following a control frequency-response curve, a second
curve was constructed in the presence of prazosin (3
mol/L), followed by a third curve in the presence of
both prazosin (3 mol/L) and PPADS (30 mol/L). Fi-
nally, in both types of experiments, a fourth curve was
constructed in the presence of tetrodotoxin (TTX; 1
mol/L) to isolate any part of the response that was due
to direct stimulation of the smooth muscle. In other
experiments, the control frequency-response curve was
repeated in the presence of guanethidine (3 mol/L)
alone or TTX (1 mol/L) alone. All antagonists were
allowed to equilibrate for 20 minutes before the fre-
quency-response curves were constructed.
Onseparatepreparations,concentration-responsecurves
were constructed both on low tone (vessels that had not
been pre-constricted with NA) or raised tone (vessels
that had been pre-constricted with NA).
At low tone, a cumulative concentration-response curve
was constructed (i.e., consecutive doses added without
wash-out of the previous dose) for NA (10 nmol/L to 1
mmol/L). Non-cumulative concentration response curves
(i.e., consecutive doses added individually following wash-
out of the previous dose) were constructed to ATP (1
mol/L to 1 mmol/L), ,-methylene ATP (,-meATP;
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0.3 mol/L to 0.1 mmol/L), 2-MeSADP (0.1 mol/L to
0.1 mmol/L) and UTP (1 mol/L to 1 mmol/L).
The concentration inducing half-maximal exposure
(EC50) concentration for NA was calculated for each
preparation and this concentration was used to pre-con-
strict the vessel. On NA pre-constricted vessels, cumula-
tive concentration-response curves were constructed for
acetylcholine (ACh; 10 nmol/L to 1 mmol/L), ATP (0.1
mol/L to 1 mmol/L), 2-MeSADP (10 nmol/L to 0.3
mmol/L), and UTP (0.1 mol/L to 1 mmol/L).
Since alteration in extracellular pH is known to affect
the response to ATP at P2X2 receptors [27], in some
experiments the effect of changing the pH of the Kreb’s
to 6.5 was examined. In these experiments, the response
to a single concentration of ATP (0.1 mmol/L) and ,-
meATP (3 mol/L) was repeated twice in Kreb’s at pH
7.2. The pH of the Kreb’s was then adjusted to pH 6.5
and added to the organ bath for 5 minutes, then the
ATP and ,-meATP responses were repeated.
A single concentration of KCl (120 mmol/L) was
added to each vessel at the end of each experiment to
give a standard contraction.
Immunohistochemistry
Isolated rat renal arteries were blocked in OCT and
frozen down in isopentane, pre-cooled in liquid nitrogen.
Using a Reichert Jung CM1800 cryostat (Leica Instru-
ments, Nubloch, Germany), 12 m sections of renal ar-
tery were cut and mounted on gelatine-coated slides
ready for immuno-staining.
The immunofluorescent localization of purinoceptors
was carried out using the revised protocol described by
Llewellyn-Smith and co-workers [28, 29]. The sections
were air-dried for 30 minutes at room temperature and
then fixed in 4% formaldehyde in 0.1 mol/L phosphate
buffer for 2 minutes at room temperature before being
washed in phosphate-buffered saline (PBS) at room tem-
perature 3 times for 5 minutes each time. Non-specific
binding sites were blocked by a 20 minute incubation
with 10% normal horse serum (NHS) in PBS containing
0.05% merthiolate (thimerosal). Primary antibodies for
the P2X1, P2X2, P2X4, P2X5, P2X6, and P2X7 receptors
were diluted to 1.25 g/mL to 5 g/mL and the P2Y1 and
P2Y2 receptor primary antibodies diluted to 1.5 g/mL
to 6 g/mL with 10% NHS-PBS-merthiolate. The P2X3
receptor primary antibody was diluted with 10% NHS
containing 0.2% Triton X-100 to 1.25 g/mL to 5 g/mL.
The specimens were then incubated overnight at room
temperature with the primary antibodies. The secondary
antibody, biotinylated donkey anti-rabbit immunoglobu-
lin G (IgG) diluted 1:500 in 1% NHS-PBS-merthiolate,
was applied and incubated for 1 hour. After washing,
the sites of the antigen-antibody binding were revealed
by using streptavidin-fluorescein [fluoroscein isothiocya-
nate (FITC)-green fluorophore] diluted 1:200 in PBS-
merthiolate. The sections were again washed and then
incubated for 5 minutes with Pontamine Sky Blue [0.1%
in 1% dimethyl sulfoxide (DMSO)/PBS] to reduce back-
ground autofluorescence staining. The specimens were
mounted with Citifluor and coverslipped.
As a control for non-specific immunoreaction, one
slide was included in each experiment on which the pri-
mary antibody had been omitted.
The sections were viewed under a Zeiss Axioplan mi-
croscope (Zeiss, Oberkochen, Germany), and selected
areas were photographed with a digital Leica DC200
(Leica Instruments) camera. The pictures were processed
using Adobe Photoshop 5.0 software (San Jose, CA, USA)
on an Apple Power Macintosh G3 (Apple, Cupertino,
CA, USA).
Drugs used
ACh, ATP, guanethidine, ,-meATP (a selective
agonist for P2X1 and P2X3 receptors [7]), merthiolate,
2-MeSADP (a selective agonist for P2Y1 receptors [8]),
NA, NHS, PPADS (a non-selective P2 antagonist [7]),
prazosin, streptavidin-fluorescein, TTX, and UTP were
purchased from Sigma Chemical Co. (Poole, UK); for-
maldehyde stabilized with 10% methanol was obtained
from AnalaR, (BDH) (Poole, UK); biotinylated donkey
anti-rabbit IgG was obtained from Jackson Immuno-
Research (West Grove, PA, USA).
Primary P2X receptor antibodies were kindly donated
by Roche Bioscience (Palo Alto, CA, USA). Primary
P2Y antibodies were obtained from Alomone Labs (Je-
rusalem, Israel).
Statistical analysis
Responses to EFS: Contractile responses in the ab-
sence and presence of PPADS, prazosin, or both, are
expressed as mean % contraction of the maximum con-
trol response  SE (N) animals. Individual frequency-
response curves are compared using a two-way analysis
of variance (ANOVA) followed by a post hoc (Tukey)
test since analysis of the data revealed it to be normally
distributed and therefore the use of this test was appro-
priate.
Low tone concentration-response curves: Concentra-
tion-response curves to NA are expressed as mean %
of the maximum contraction  SE (N). The EC50 values
for NA in the absence and presence of the endothelium
were compared using an unpaired Student t test. The
EC50 concentration was used to pre-contract the ves-
sel. Contraction-response curves to ATP, ,-meATP,
2-MeSADP, and UTP are expressed as mean % of the
KCl-induced contraction  SE (N). Individual con-
centration-response curves are compared using a two-
way analysis of variance (ANOVA) followed by a post
hoc test.
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Raised-tone concentration-response curves: Relaxant
responses to ACh are expressed as mean % reduction
of the NA-induced contraction  SE (N).
All statistical analyses were performed by means of
the software Prism 3.0 (GraphPad Software, Inc., San
Diego, CA, USA). A probability level of P  0.05 was
taken as significant for both the ANOVA and t tests.
RESULTS
Organ bath pharmacology
Electrical field stimulation. Electrical field stimulation
(75 V, 0.1 milliseconds, 1 to 32 Hz, 10 second stimulation
every 5 minutes) of the renal artery induced frequency-
dependent contractions that were guanethidine (3mol/L)
and TTX (1 mol/L) sensitive indicating that the re-
sponses were sympathetic and nerve-mediated in origin
(Fig. 1A).
Frequency-response curves in the absence of any block-
ing agents were constructed. The control curves were re-
peated in the presence of either PPADS (30 mol/L) or
prazosin (3 mol/L) alone, and finally in the presence
of both antagonists. PPADS (30 mol/L) alone caused
a significant (P  0.0001) inhibition of the control fre-
quency-response curve (Fig. 1B). In the presence of
PPADS, the addition of prazosin (3 mol/L) resulted in
the almost total inhibition (P  0.0001) of the response
to EFS (Fig. 1B).
Prazosin (3 mol/L) alone caused a large, significant
(P  0.0001) inhibition of the control frequency-
response curve (Fig. 1C). In the presence of prazosin,
the addition of PPADS (30 mol/L) significantly (P 
0.001) blocked the residual response to EFS (Fig. 1C).
Exogenously applied agonists. On low-tone prepara-
tions of renal artery, NA (10 nmol/L to 1 mmol/L) induced
concentration-dependent, sustained vasoconstrictions and
concentration-response curves were constructed (Fig. 2A).
From the individual concentration-response curves the
EC50 concentration was calculated. This concentration
was then used to pre-constrict the vessels.
Concentration response curves to NA from vessels
with an intact endothelium were compared to those with
a disrupted endothelium. The concentration response
curves to NA from renal arteries with a disrupted endo-
thelium were found to be significantly different (P 
0.001) from those vessels whose endothelium was intact
(Fig. 2A), indicating that in the absence of the endothe-
lium NA was inducing larger constrictions than in the
presence of the endothelium.
The mean pD2 value (log EC50 concentration) for
NA was calculated in the absence and presence of the
endothelium. These were found to be 5.38  0.10 (N 	
11) in the absence of the endothelium and 5.20  0.14
(N 	 10) in the presence of the endothelium. These
values were compared using an unpaired Student t test
Fig. 1. Effect of antagonists on electrical field stimulation (EFS) of the
rat renal artery (75 V, 0.1 milliseconds, 1 to 32 Hz, 10 second stimulation
every 5 minutes). (A ) Frequency-response curves in the absence (con-
trol; N 	 4) and presence of either guanethidine (3 mol/L; N 	 4) or
TTX (1 mol/L; N 	 4). (B ) Frequency-response curves in the absence
(control; N	 6) and presence of pyridoxalphosphate-6-azophenyl-2,4-
disulfonic acid (PPADS) (30 mol/L; N 	 6). In the presence of both
PPADS (30 mol/L) and prazosin (3 mol/L; N 	 6). (C ) Frequency-
response curves in the absence (control; N	 6) and presence of prazosin
(3 mol/L; N 	 6). Finally, in the presence of both prazosin (3 mol/L)
and PPADS (30 mol/L; N 	 6). All symbols are mean  SE (unless
error bars masked by the symbol), expressed as % of the maximum
control response. Statistical significance was tested by two-way analysis
of variance (ANOVA). ***P  0.0001 (applicable to the whole curve).
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Fig. 2. Effects of exogenously applied agonists on the rat renal artery.
(A ) Cumulative concentration-response curves for noradrenaline (NA)
(10 nmol/L to 1 mmol/L) expressed as % of the maximum response,
in the absence (N 	 11) and presence (N 	 10) of the endothelium.
(B ) Cumulative concentration-response curves for acetylcholine (Ach)
(10 nmol/L to 1 mmol/L; N 	 13) expressed as % relaxation of the NA
(EC50 concentration) contraction. (C ) Non-cumulative concentration-
response curves for ,-meATP (0.3 mol/L to 0.1 mmol/L; N 	 6),
2-MeSADP (0.1 mol/L to 0.1 mmol/L; N 	 5), uridine triphosphate
(UTP) (1 mol/L to 1 mmol/L; N 	 5) and adenosine triphosphate
(ATP) (1 mol/L to 1 mmol/L; N 	 5) expressed as % of the KCl (120
and were not found to be statistically significantly differ-
ent (P 	 0.2820).
On NA pre-constricted preparations of renal artery,
ACh (10 nmol/L to 1 mmol/L; N 	 13) induced con-
centration-dependent vasodilatation and concentration-
response curves were constructed (Fig. 2B). The ability
of an individual preparation of renal artery to dilate in
the presence of ACh was taken as an indication of the
integrity of the endothelium. In those vessels where the
endothelium had been disrupted, ACh failed to induce
vasodilatation.
On low-tone preparations in the presence of the en-
dothelium, ,-meATP (0.3 mol/L to 0.1 mmol/L),
2-MeSADP (0.1 mol/L to 0.1 mmol/L), ATP (1 mol/L
to 1 mmol/L), and UTP (1 mol/L to 1 mmol/L), all
induced concentration-dependent contractions that were
not sustained, and non-cumulative concentration-response
curves were constructed for each agonist (Fig. 2C). The
order of potency for these agonists was: ,-meATP 

2MeSADP
UTP
ATP. The curves to UTP and ATP
were compared using a two-way ANOVA test, and the
curves were seen to be statistically different from each
other (P  0.05), with UTP being slightly more potent
than ATP.
As none of the P2 agonists reached a maximum re-
sponse, pD2 values could not be calculated and the results
were expressed as a % of the KCl contraction.
On NA pre-constricted preparations of renal artery
neither ATP (0.1 mol/L to 1 mmol/L; Fig. 3A), 2-MeS-
ADP (10 nmol/L to 0.3 mmol/L; Fig. 3B), nor UTP (0.1
mol/L to 1 mmol/L; Fig. 3C) induced vasodilatation, in
the presence of either an intact or disrupted endothe-
lium; indeed, UTP increased the tone of the vessel still
further.
Altering the pH of the Kreb’s from 7.2 to 6.5 had no
potentiating effect on the responses to either ATP or
,-meATP. Control constrictions to ATP (0.1 mmol/L)
at pH 7.2 (taken as 100%), were found to be 52.5 
18.7% (N 	 3) in the presence of pH 6.5, which was not
significantly different from the control (P 	 0.1263),
whereas control constrictions to ,-meATP (3 mol/L)
(taken as 100%), were 45.9  5.5% (N 	 3) in the
presence of pH 6.5, which was significantly different from
the control (P  0.01). The alteration in pH was found
to generally inhibit the vessel from constricting.
Immunohistochemistry
P2X receptor staining. P2X1 receptor immunoreactiv-
ity was clearly present on the smooth muscle of the renal
mmol/L) contraction. All symbols are mean  SE (unless error bars
masked by the symbol). Statistical significance was tested by two-way
analysis of variance (ANOVA). **P  0.001 (applicable to the whole
curve).
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Fig. 3. Examples of original traces of the effect of exogenously applied
agonists on the rat renal artery. (A ) Cumulative concentration-response
curves to adenosine triphosphate (ATP) (1 to 1000 mol/L) on a nor-
adrenaline (NA) (EC50 concentration) pre-constricted renal artery in
the absence of the endothelium. (B ) Cumulative concentration-
response curve to 2-MeSADP (0.1 to 100 mol/L) on a NA (EC50
concentration) pre-constricted renal artery in the presence of the endo-
thelium. (C ) Cumulative concentration-response curves to uridine tri-
phosphate (UTP) (0.1 to 100 mol/L) on a NA (EC50 concentration)
pre-constricted renal artery in the presence of the endothelium.

Fig. 4. P2X1, P2X2, P2Y1, and P2Y2 immunostaining of the rat renal artery. (A ) Specific immunoreactivity for P2X1 receptors was clearly present
in the smooth muscle of the renal artery. (B ) P2X2 receptor immunoreactivity was observed in the smooth muscle of the renal artery. (C and D )
Controls consisting of the omission of the primary antibody to P2X1 and P2X2, respectively. (E ) P2Y1 receptor immunoreactivity was present in
the smooth muscle of the renal artery. (F ) P2Y2 receptor immunoreactivity was expressed in the smooth muscle of the renal artery. (G and H )
Controls consisting of the omission of the primary antibody to P2Y1 and P2Y2, respectively. Magnification of all plates, 400.
artery (N 	 3; Fig. 4a). P2X2 receptor immunoreactivity
was also observed on the smooth muscle of the renal
artery (N	 3; Fig. 4b). No P2X1 or P2X2 immunoreactiv-
ity was observed on the vascular endothelium in sections
of the renal artery. No immunostaining for P2X3, P2X4,
P2X5, P2X6, or P2X7 receptors was observed for the renal
artery. To ensure that the immunostaining observed was
specific, controls were included from which the primary
antibodies had been omitted (N 	 3; Figure 4 C and D).
Some low-level background fluorescence remained.
P2Y receptor staining. P2Y1 receptor immunoreactiv-
ity was observed on the smooth muscle of the renal artery
(N 	 3; Fig. 4E). P2Y2 receptor immunoreactivity was
also observed on the smooth muscle of the renal artery
(N 	 3; Fig. 4F), although usually at a lower intensity
than that observed for P2Y1 receptors. To ensure all
staining observed was specific, controls were included
from which the primary antibodies had been omitted (N	
3; Figure 4 G and H).
DISCUSSION
One aim of this study of the rat renal artery was to
investigate whether ATP is a cotransmitter with NA
in sympathetic nerves to produce vasoconstriction, as
occurs in many other blood vessels [7, 30].
Evidence is presented that ATP is indeed a cotransmit-
ter with NA and induces vasoconstriction. The fact that
guanethidine and TTX inhibit the response to EFS indi-
cates that sympathetic nerves are being stimulated. Fur-
ther evidence obtained from the use of antagonists shows
that both ATP and NA are being released from these
nerves. The 1-adrenoceptor antagonist, prazosin, inhib-
ited a large proportion (over 90%) of the response to
EFS, while the non-selective P2X receptor antagonist,
PPADS, only produced about 5 to 10% inhibition at
most stimulation frequencies. PPADS was used as the
inhibitor of P2X1-mediated vasoconstrictions in this in-
stance, since the more recently developed selective P2X1
antagonist 2,3-O-(2,4,6-trinitrophenyl) ATP (TNP-ATP)
is known to breakdown rapidly when used in whole tissue
studies such as this study [9]. In previous studies of the
rat isolated kidney vascular bed, the vasoconstrictor re-
sponse due to low frequencies of stimulation (2 Hz) was
entirely due to the release of ATP [31, 32]. In addition
to the results from perivascular nerve stimulation, the
effect of exogenously applied agonists supports the con-
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cept of cotransmission. Exogenously applied NA and
ATP mimicked the responses to nerve stimulation. NA
acted on 1-adrenoceptors to produce sustained contrac-
tions, while ATP, and its stable analog ,-meATP, act
on P2X1 receptors to produce a faster transient contrac-
tion.
In common with other blood vessels such as the rat
mesenteric, pulmonary, basilar, and coronary arteries
where P2X1 receptors have been visualized immuno-
histochemically on vascular smooth muscle cells [33–35],
the presence of P2X1 receptors on the vascular smooth
muscle of the rat renal artery was demonstrated by im-
munostaining. P2X2 receptor immunostaining was also
shown to be present in the rat renal artery. The question
as to which P2X receptor subtype is responsible for the
vasoconstriction was partly answered by the contractile
activity of ,-meATP. ,-meATP is a selective agonist
for P2X1 and P2X3 receptors, but is inactive at P2X2
receptors. Since P2X3 receptor immunostaining has not
been demonstrated in the renal vascular smooth muscle,
it can be assumed that the vasoconstriction responses
seen to ,-meATP are a consequence of the activation
of P2X1 receptors on the smooth muscle of the renal
artery. The presence of P2X2 receptors on the smooth
muscle of the rat renal artery is by no means unusual.
Other vessels also exhibit immunoreactivity to P2X2 re-
ceptors, including the rat mesenteric and pulmonary ar-
teries, aorta, and urinary bladder veins [33], and mRNA
for P2X2 receptors was found in the smooth muscle of
rat coronary vessels and aorta [36]. A reduction in pH
is known to potentiate responses to ATP at recombinant
P2X2 receptors [27], and in the rat tail circulation, pu-
rinergic sympathetically-mediated vasoconstriction was
found to be sensitive to changes in pH via a P2X receptor
[37]. However, P2X2 receptors are unlikely to be a major
contributor to the contractile responses of ATP in the
rat renal artery, since alteration in the pH of the Kreb’s
solution, from 7.2 to 6.5, had no potentiating effect on
responses to ATP.
No endothelium-dependent vasodilatation was pro-
duced in response to either ATP or UTP in the rat renal
artery. However, we have shown, as have others, that
ACh acts via the renal artery endothelium to induce
relaxation in an NO-independent manner [38, 39]. Simi-
larly, an inhibitory adenosine A2b receptor located on
rat renal endothelial cells and stimulating the release of
NO has been identified [40]. Agonists for P2 receptors
on raised tone preparations of rat renal artery do not
induce vasodilatation either in the presence or absence
of the endothelium. On the contrary, 2-MeSADP and
UTP, agonists for P2Y1 and P2Y2 receptors, respectively
[8, 41], both induced vasoconstriction of this vessel. Since
both agonists were active it would imply that both recep-
tors are present, and since constriction occurred in either
the absence or presence of the vascular endothelium,
their location can be assumed to be on the smooth mus-
cle. This is confirmed by immunohistochemical staining
of this vessel for P2Y receptors, where both P2Y1 and
P2Y2 receptor fluorescence was observed, concentrated
on the smooth muscle of the renal artery. Other blood
vessels exhibit constriction in response to P2Y agonists.
For example, in the rat mesenteric artery, UTP induces
constriction acting via a P2Y2 receptor [34], and the rat
aorta, tail artery, and saphenous vein constrict in re-
sponse to UTP [42–44]. Why this vessel expresses two
different P2Y receptors, both mediating vasoconstric-
tion, and why purine and pyrimidine nucleotides do not
elicit vasodilatation is not clearly understood. The rat
renal artery is particularly short (approximately 4 to
5 mm in length) compared to the renal arteries of humans
and rabbits, which are considerably longer. Both human
and rabbit renal arteries possess endothelial P2Y recep-
tors which induce endothelium-dependent vasodilata-
tion via NO [26]; this species difference may be related
to the difference in length of the vessels. It is possible
that stimulation of either of these P2 receptors may lead
to long-term trophic actions on cell growth, proliferation,
and cell death [45]; it is perhaps significant that the re-
sponse of the isolated rat renal artery to these agonists
is the opposite of their effects upon the renal vascular
bed. Perfused rat kidneys, when exposed to 2-MeSATP,
respond with vasodilatation, this response being blocked
by the NOS inhibitor N nitro-l-arginine methyl ester
[46], indicating the presence of P2Y1 receptors on the
vascular endothelium. Release of an agent that markedly
dilates the vascular bed but acts to constrict the artery
feeding the bed may act as a feedback safety mechanism
to minimize rapid dilatation of the vascular bed.
CONCLUSION
This study has shown cotransmission of ATP and NA
in the rat renal artery and in common with a minority of
other blood vessels, the presence on the vascular smooth
muscle of P2X1, P2Y1, and P2Y2 receptors, all of which
mediate vasoconstriction of the vessel. This vessel ap-
pears to be devoid of a nucleotide receptor inducing
vasodilatation.
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